   2.3.1.17 | medicine |
patients with high levels of tumoral N-acetyl-L-aspartate and its biosynthetic enzyme, aspartate N-acetyltransferase (NAT8L), have worse overall survival than patients with low levels of N-acetyl-L-aspartate and NAT8L. The overall survival duration of patients with higher-than-median N-acetyl-L-aspartate levels (3.6 years) is lower than that of patients with lower-than-median N-acetyl-L-aspartate levels (5.1 years). High NAT8L gene expression in other cancers (melanoma, renal cell, breast, colon, and uterine cancers) is associated with worse overall survival. NAT8L silencing reduces cancer cell viability and proliferation. In orthotopic mouse models (ovarian cancer and melanoma), NAT8L silencing reduces tumor growth statistically significantly |
757461 |
